The Relationship between Serum Procalcitonin and Dialysis Adequacy in Peritoneal Dialysis Patients
Background: To detect the serum procalcitonin (PCT) levels of peritoneal dialysis (PD) patients.
Methods: We analyzed the relationship between the PCT Level and dialysis adequacy. We studied 120 peritoneal dialysis patients without signs of infection in Affiliated Hangzhou First People's Hospital and 120 controls from Jan 2014 to Apr 2016. PCT and high sensitivity C-reactive protein (hs-CRP) were detected. 120 PD patients were divided into two groups according to the dialysis adequacy. A correlation analysis was processed between the PCT level and the total solute clearance (Kt/V). The value of PCT for identifying the dialysis adequacy in PD patients was assessed by ROC curve analysis.
Results: PCT level in serum of PD group (0.29±0.24 ng/ml) was higher than that of the control group (0.02±0.01 ng/ml) (P<0.01). Compared with the inadequate dialysis group (0.5±0.37 ng/ml), the PCT Level of the adequate dialysis group (0.23±0.15 ng/ml) was lower (P<0.01). There were negative correlations between PCT and Kt/v(r=-0.451), Prealbumin (PA) (r=-0.258), Glomerular Filtration Rate (eGFR; r=-0.280), while there was positive correlation between PCT and Hypersensitive c-reactive protein (r=0.458) (P<0.01). At a serum PCT cut-off value of 0.283 ng/ml, the sensitivity and specificity for identifying the dialysis adequacy in PD patients were 0.913 and 0.805 respectively. The serum levels of PCT in peritoneal dialysis patients were significantly higher than the levels in healthy controls.
Conclusion: The serum level of PCT can be used as an indirect maker to evaluate the adequacy of dialysis.
2. Pipili C, Grapsa E, Tripodaki ES, et al (2015). Changes in skeletal muscle mi-crocirculation after a hemodialysis session correlates with adequacy of dialysis. Int J Nephrol Renovasc Dis, 8: 59-64.
3. Trimarchi H, Dicugno M, Muryan A, et al (2013). Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires), 73 (5): 411-6.
4. Dahaba AA, Rehak PH, List WF (2003). Procalcitonin and C-reactive protein plasma concentrations in nonseptic ure-mic patients undergoing hemodialysis. In-tensive Care Med, 29 (4): 579-83.
5. Herget-Rosenthal S, Klein T, Marggraf G, et al (2005). Modulation and source of pro-calcitonin in reduced renal function and renal replacement therapy. Scand J Immu-nol, 61 (2): 180-6.
6. Contou D, D'Ythurbide G, Messika J, et al (2014). Description and predictive factors of infection in patients with chronic kid-ney disease admitted to the critical care unit. J Infect, 68 (2): 105-15.
7. Wang X, Sun Y, Shao X (2019). Predictive value of procalcitonin for infection of pa-tients with type-2 diabetes mellitus. Exp Ther Med, 18 (1): 722-8.
8. Fu Y, Chen J, Cai B, et al (2012). The use of PCT, CRP, IL-6 and SAA in critically ill patients for an early distinction between candidemia and Gram positive/negative bacteremia. J Infect, 64 (4): 438-40.
9. Meisner M, Lohs T, Huettemann E, et al (2001). The plasma elimination rate and urinary secretion of procalcitonin in pa-tients with normal and impaired renal function. Eur J Anaesthesiol, 18 (2): 79-87.
10. Level C, Chauveau P, Delmas Y, et al (2001). Procalcitonin: a new marker of inflamma-tion in haemodialysis patients? Nephrol Dial Transplant, 16 (5): 980-6.
11. Steinbach G, Bölke E, Grünert A, et al (2004). Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr, 116 (24): 849-53.
12. Boonyarittipong M, Kurathong S, Trakarnvanich T (2019). Interleukin-6, procalcitonin, and vascular endothelial growth factor in plasma and dialysate correlate with dialysis adequacy in contin-uous ambulatory peritoneal dialysis pa-tients. Clin Nephrol, 92 (5): 273-5.
|Issue||Vol 50 No 3 (2021)|
|Procalcitonin Adequacy of dialysis Microinflammation Hypoproteinemia|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|